Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

9.740 +0.080 (+0.83%)
Official Closing Price Updated: 7:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces CEO Transition
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Financial Results For First Quarter 2023
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
From Emergent BioSolutions
Via GlobeNewswire
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
From Emergent BioSolutions
Via GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
Emergent partners with the Armed Forces Research Institute of Medical Sciences for its capabilities in Chikungunya virus surveillance and field studies 
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reports Financial Results For Third Quarter 2022
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines
From Emergent BioSolutions
Via GlobeNewswire
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022
From Emergent BioSolutions
Via GlobeNewswire
Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.
From Shuman, Glenn & Stecker
Via Business Wire
NYSE:EBS Long Term Investor Alert: Investigation of Potential Wrongdoing at Emergent BioSolutions Inc
San Diego, CA -- (SBWIRE) -- 08/23/2021 -- Certain directors of Emergent BioSolutions Inc are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent BioSolutions Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.